[go: up one dir, main page]

PE20050352A1 - Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos - Google Patents

Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos

Info

Publication number
PE20050352A1
PE20050352A1 PE2004000738A PE2004000738A PE20050352A1 PE 20050352 A1 PE20050352 A1 PE 20050352A1 PE 2004000738 A PE2004000738 A PE 2004000738A PE 2004000738 A PE2004000738 A PE 2004000738A PE 20050352 A1 PE20050352 A1 PE 20050352A1
Authority
PE
Peru
Prior art keywords
radical
indol
pyrrolidin
sulfonamide
ethyl
Prior art date
Application number
PE2004000738A
Other languages
English (en)
Inventor
Zueras Alberto Dordal
Soler Xavier Codony
Vidal Ramon Merce
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of PE20050352A1 publication Critical patent/PE20050352A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE SULFONAMIDA, DE FORMULA Ia, EN LA QUE R1 ES UN RADICAL CICLOALIFATICO SATURADO O INSATURADO, O UN RADICAL -NR8R9; R2, R3, R4, R5 Y R6 SON CADA UNO H, HALOGENO, NITRO, ENTRE OTROS; R7 ES H, RADICAL ALIFATICO LINEAL O RAMIFICADO; R8 Y R9 SON CADA UNO H O RADICAL ALIFATICO LINEAL O RAMIFICADO; n ES 0-4. TAMBIEN REFERIDO A UN PROCEDIMIENTO PARA LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 5-CLORO-3-METIL-N-{1[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}BENZO[b]TIOFENO-2-SULFONAMIDA, N-{1-[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}IMIDAZO[2,1-b]TIAZOL-5-SULFONAMIDA Y 2-(NAFTALEN-1-IL)-N-{1-[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}ETANOSULFONAMIDA, ENTRE OTROS. DICHOS COMPUESTOS INTERVIENEN EN LA REGULACION DEL RECEPTOR 5-HT6 Y SON UTILES PARA EL TRATAMIENTO DE LA OBESIDAD, BULIMIA, CAQUEXIA, ENTRE OTRAS
PE2004000738A 2003-07-30 2004-08-02 Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos PE20050352A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200301808A ES2222830B1 (es) 2003-07-30 2003-07-30 Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.

Publications (1)

Publication Number Publication Date
PE20050352A1 true PE20050352A1 (es) 2005-06-12

Family

ID=34130542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000738A PE20050352A1 (es) 2003-07-30 2004-08-02 Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos

Country Status (23)

Country Link
US (1) US7414070B2 (es)
EP (1) EP1648444B1 (es)
JP (1) JP2007500167A (es)
KR (1) KR20060036457A (es)
CN (1) CN1832739A (es)
AR (1) AR045158A1 (es)
AT (1) ATE432698T1 (es)
AU (1) AU2004262487A1 (es)
BR (1) BRPI0413001A (es)
CA (1) CA2534136A1 (es)
DE (1) DE602004021383D1 (es)
EC (1) ECSP066323A (es)
ES (2) ES2222830B1 (es)
IL (1) IL172750A0 (es)
MX (1) MXPA06001130A (es)
NO (1) NO20060506L (es)
NZ (1) NZ545298A (es)
PE (1) PE20050352A1 (es)
PT (1) PT1648444E (es)
RU (1) RU2006105791A (es)
TW (1) TW200510433A (es)
WO (1) WO2005013979A1 (es)
ZA (1) ZA200600418B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
EP2020230B1 (en) 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
DE19753522A1 (de) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
JP2002167376A (ja) * 2000-11-30 2002-06-11 Mercian Corp 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途
AU2002236730B2 (en) * 2001-01-30 2006-06-15 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor
US6488243B2 (en) * 2001-04-06 2002-12-03 Seong Tae Kim Bag holder for hanging on rims of miscellaneous items
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
DE602004016491D1 (de) * 2003-05-09 2008-10-23 Esteve Labor Dr Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen

Also Published As

Publication number Publication date
NO20060506L (no) 2006-01-31
JP2007500167A (ja) 2007-01-11
BRPI0413001A (pt) 2006-09-26
ZA200600418B (en) 2007-03-28
EP1648444A1 (en) 2006-04-26
US7414070B2 (en) 2008-08-19
ECSP066323A (es) 2006-08-30
IL172750A0 (en) 2006-04-10
AR045158A1 (es) 2005-10-19
ATE432698T1 (de) 2009-06-15
MXPA06001130A (es) 2006-04-24
ES2222830A1 (es) 2005-02-01
TW200510433A (en) 2005-03-16
NZ545298A (en) 2008-06-30
CA2534136A1 (en) 2005-02-17
KR20060036457A (ko) 2006-04-28
ES2222830B1 (es) 2006-02-16
US20070185207A1 (en) 2007-08-09
CN1832739A (zh) 2006-09-13
EP1648444B1 (en) 2009-06-03
DE602004021383D1 (de) 2009-07-16
AU2004262487A1 (en) 2005-02-17
WO2005013979A1 (en) 2005-02-17
RU2006105791A (ru) 2007-09-20
ES2327846T3 (es) 2009-11-04
PT1648444E (pt) 2009-09-03

Similar Documents

Publication Publication Date Title
PE20050280A1 (es) Derivados de 6-indolilsulfonamidas y su preparacion como medicamentos
ECSP056097A (es) Antagonistas del receptor cgrp
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
UY28940A1 (es) Derivados de quinazolina
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
PE20081689A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
AR024379A1 (es) Gamma-carbolinas fusionadas heterociclicas sustituidas
PE20061088A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a
ATE466860T1 (de) Cgrp-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten
NI200300053A (es) Derivados del tropano utiles en terapia.
PE20120881A1 (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PE20060336A1 (es) Compuestos derivados de 1-amino-ftalazina como moduladores de mch1
PE20081876A1 (es) Aminoamidas como antagonistas de orexina
PE34297A1 (es) Ligandos especificos del neuropeptido y1
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
ES2086579T3 (es) Antagonista de leucotrieno b4.

Legal Events

Date Code Title Description
FC Refusal